Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical value of a screening tool for tumor predisposition syndromes in childhood cancer patients (TuPS): a prospective, observational, multi-center study.
Postema FAM, Hopman SMJ, de Borgie CAJM, Aalfs CM, Anninga JK, Berger LPV, Bleeker FE, Dommering CJ, van Eijkelenburg NKA, Hammond P, van den Heuvel-Eibrink MM, Hol JA, Kors WA, Letteboer TGW, Loeffen JLCM, Meijer L, Olderode-Berends MJW, Wagner A, Hennekam RC, Merks JHM. Postema FAM, et al. Among authors: anninga jk. Fam Cancer. 2021 Oct;20(4):263-271. doi: 10.1007/s10689-021-00237-1. Epub 2021 Mar 9. Fam Cancer. 2021. PMID: 33686467 Free PMC article.
Validation of a clinical screening instrument for tumour predisposition syndromes in patients with childhood cancer (TuPS): protocol for a prospective, observational, multicentre study.
Postema FA, Hopman SM, de Borgie CA, Hammond P, Hennekam RC, Merks JH; TuPS study group; Aalfs CM, Anninga JK, Berger LP, Bleeker FE, de Bont ES, de Borgie CA, Dommering CJ, van Eijkelenburg NK, Hammond P, Hennekam RC, van den Heuvel-Eibrink MM, Hopman SM, Jongmans MC, Kors WA, Letteboer TG, Loeffen JL, Merks JH, Olderode-Berends MJ, Postema FA, Wagner A; TuPS study group. Postema FA, et al. Among authors: anninga jk. BMJ Open. 2017 Jan 20;7(1):e013237. doi: 10.1136/bmjopen-2016-013237. BMJ Open. 2017. PMID: 28110285 Free PMC article.
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup.
Lancia C, Anninga JK, Sydes MR, Spitoni C, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M. Lancia C, et al. Among authors: anninga jk. Cancer Chemother Pharmacol. 2019 May;83(5):951-962. doi: 10.1007/s00280-019-03797-3. Epub 2019 Mar 16. Cancer Chemother Pharmacol. 2019. PMID: 30879111 Free PMC article.
Prognostic factors in pulmonary metastasized high-grade osteosarcoma.
Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PC, Lankester AC, Gelderblom H. Buddingh EP, et al. Among authors: anninga jk. Pediatr Blood Cancer. 2010 Feb;54(2):216-21. doi: 10.1002/pbc.22293. Pediatr Blood Cancer. 2010. PMID: 19890902
30 results